Westgeest HM, Kuppen MCP, van den Eertwegh AJM, et al. - This study was undertaken to explore the effect of the introduction of the new life-prolonging drugs (LPDs) on treatment patterns and overall survival (OS) in castration-resistant prostate cancer (CRPC) patients over time. Researches enrolled CRPC patients diagnosed from 2010–2016 in this observational, retrospective CAPRI registry (20 hospitals) and followed up with them until 2018. They further examined two subgroups: treatment-naïve patients (subgroup 1, n = 3,600) and post-docetaxel patients (subgroup 2, n = 1,355). The data indicated that a larger proportion of mCRPC patients was treated with LPDs since 2010, which was related to an increased median OS. Use of any LPD increased in both subgroups, from 57% (2010–2011) to 69% (2014–2015) in subgroup 1 and from 65% (2011–2012) to 79% (2015–2016) in subgroup 2. Chemotherapy as first mCRPC-treatment (i.e., docetaxel) and first post-docetaxel treatment (i.e., cabazitaxel or docetaxel rechallenge) decreased (46 to 29% in subgroup 1 and and 20 to 9% in subgroup 2), while the use of androgen-receptor targeting treatments increased from 11% to 39% in subgroup 1 and 46% to 64% in subgroup 2. In subgroup 1, median OS from diagnosis CRPC increased from 28.5 months to 31.0 months. In subgroup 2, mOS from progression on docetaxel increased from 7.9 months to 12.5 months.